US-based generics company, Mylan, has tied up with the Indian biotech company, Biocon, to develop, manufacture and commercialise high value generic biological drugs for the global market. At risk of falling behind in the biogenerics race, the deal propels Mylan into the league of other leading generics manufacturers in the field.